← Back to Search

Monoclonal Antibodies

Vudalimab for Cancer

Phase 2
Research Sponsored by Xencor, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adult (age ≥ 18 years)
Cancer must have progressed after treatment with all approved and medically appropriate therapies or have no appropriate available therapies
Must not have
Be younger than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up12 weeks
Awards & highlights
No Placebo-Only Group

Study Summary

This trial will test if XmAb20717 is safe and effective in treating patients with certain advanced gynecologic or genitourinary cancers.

Eligible Conditions
  • Metastatic Castration Resistant Prostate Cancer
  • Ovarian Cancer
  • Clear Cell Carcinoma
  • Endometrial Cancer
  • Cervical Cancer

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
You are 18 years old or older.
Your cancer has gotten worse after trying all the approved treatments, or there are no other suitable treatments available for you.
Your specific type of cancer has been confirmed by a doctor and additional tests.
You have advanced prostate cancer that meets certain criteria for being high-risk and resistant to traditional treatments.
You are in good enough health to carry out daily activities without any major issues.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
ORR as assessed by RECIST 1.1 criteria (efficacy)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: vudalimabExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Xencor, Inc.Lead Sponsor
27 Previous Clinical Trials
2,303 Total Patients Enrolled
1 Trials studying Prostate Cancer
78 Patients Enrolled for Prostate Cancer
ICON plcIndustry Sponsor
76 Previous Clinical Trials
20,137 Total Patients Enrolled
1 Trials studying Prostate Cancer
374 Patients Enrolled for Prostate Cancer
Barbara Hickingbottom, MDStudy DirectorXencor, Inc.
6 Previous Clinical Trials
468 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the U.S. Food and Drug Administration granted authorization for XmAb20717?

"Our experts at Power assigned XmAb20717 a score of 2 since there is evidence to suggest its safety, but no clinical results back up its efficacy."

Answered by AI

Is enrollment for this trial still available to those seeking treatment?

"According to the data on clinicaltrials.gov, this medical trial is actively seeking participants. It was originally posted on July 21st 2022 and updated most recently on July 19th of that same year."

Answered by AI

To what extent is participation in this research project being observed?

"To execute this research, ICON plc needs to acquire 150 suitable patients. The two trial locations are Valkyrie Clinical Trials (Los Angeles) and Comprehensive Cancer Centers of Nevada-Southern Hills (Las Vegas)."

Answered by AI

Who else is applying?

What site did they apply to?
Winship Cancer Institute, Emory University
What portion of applicants met pre-screening criteria?
Did not meet criteria
~73 spots leftby Mar 2025